Weekly Update: December 20 to December 31, 2021. The website analysis and mapping will be updated every two weeks starting December 2021.
| Asadi M, Diabetes Metab Syndr, 2021 |
Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. |
| Bonifacio L, Antimicrob Resist Infect Control, 2021 |
Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. Standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) |
| Bruen C, SSRN, 2021 |
Auxora Improves Outcomes in Patients With Severe COVID-19 Pneumonia: A Randomized Clinical Trial |
| Chuah CH, Clin Infect Dis, 2021 |
Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial. |
| Finberg RW, Open Forum Infect Dis, 2021 |
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19. |
| Fralick M, medrxiv, 2021 |
Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial |
| Gottlieb RL, N Engl J Med, 2021 |
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. |
| Jayk Bernal A, N Engl J Med, 2021 |
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. |
| Leucker TM, JACC Basic Transl Sci, 2021 |
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. |
| Sarhan RM, J Infect Public Health, 2021 |
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. |
| Self WH, Lancet Infect Dis, 2021 |
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. |
| Zhuravel SV, EClinicalMedicine, 2021 |
Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. |
0 new or updated vaccine observational studies with results are available on our website: see here
| Arruda E A G, medrxiv, 2021 |
Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections |
| Asgardoon M, ResearchSquare, 2021 |
Efficacy of Levamisole with Standard Care Treatment vs Standard Care in Clinical Presentations of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial |
| Babalola O, ResearchSquare, 2021 |
A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria |
| Bar KJ, J Clin Invest, 2021 |
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. |
| Byakika-Kibwika P, BMC Infect Dis, 2021 |
Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. |
| Cannellotto M, Emerg Med J, 2021 |
Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial. |
| Chew KW, medrxiv, 2021 |
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19 |
| Davoodi L, Int J Cardiol Heart Vasc, 2021 |
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. |
| Diaz R, JAMA Netw Open, 2021 |
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. |
| Faramarzi H, medrxiv, 2021 |
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial |
| Gaughan E, medrxiv, 2021 |
GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of the safety, pharmacokinetics, and potential therapeutic value |
| Haeberle H, medrxiv, 2021 |
Inhaled Prostacyclin Improves Oxygenation in Patients with COVID-19-induced Acute Respiratory Distress Syndrome |
| Holm K, BMC Res Notes, 2021 |
Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. |
| Holubar M, medrxiv, 2021 |
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial |
| Huang L, medrxiv, 2021 |
Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial |
| Isa F, medrxiv, 2021 |
Repeat Subcutaneous Administration of REGEN-COV(R) in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19 |
| Kazempour M, Iran J Pharm Res, 2021 |
Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19. |
| Marcos M, Thromb Haemost, 2021 |
Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial. |
| McKinnon JE, Int J Infect Dis, 2021 |
Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. |
| Merchante N, Antimicrob Agents Chemother, 2021 |
Early Use of Sarilumab in Patients Hospitalised with COVID-19 Pneumonia and Features of Systemic Inflammation. |
| Millat-Martinez P, medrxiv, 2021 |
Convalescent plasma for outpatients with early COVID-19 |
| Montalvan E, Chest, 2021 |
High-dose vs low-dose dexamethasone in patients with covid-19 in a tertiary hospital in western honduras |
| Mordyk A, Infektsionnye Bolezni, 2021 |
Interferon alpha-2b in comprehensive treatment of patients with covid-19 |
| Morici N, merdrxiv, 2021 |
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial |
| Nair PR, Respir Care, 2021 |
Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia. |
| Novartis Pharmaceuticals |
Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) |
| Ortigoza MB , JAMA Intern Med, 2021 |
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial |
| Ospina-Tascon GA, JAMA, 2021 |
Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. |
| Panda PK, Clin Pharmacol, 2021 |
Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. |
| Pupim L, Ann. Rheum. Dis, 2021 |
Mavrilimumab improves outcomes in phase 2 trial in non-mechanically-ventilated patients with severe covid-19 pneumonia and systemic hyperinflammation |
| Ravishankar R, SSRN, 2021 |
Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Efficacy, Safety and Tolerability of Antiviral Drug Umifenovir vs Standard Care of Therapy in Non-Severe Covid-19 Patients |
| Reis G, Lancet Glob. Health, 2021 |
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. |
| Roshon M, Infect Dis Ther, 2021 |
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection. |
| Sabitovi A, Antibiot. Khimioter., 2021 |
The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19 |
| Seong S, ResearchSquare, 2021 |
A multicenter, randomized, double-blind, placebo-controlled phase ii trial of intravenous inflammasome inhibitor (NuSepin) for the treatment of COVID-19 patients |
| Shenoy S , medrxiv, 2021 |
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. |
| Song JY, medrxiv, 2021 |
Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity |
| Sullivan D, medrxiv, 2021 |
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma |
| Taboada M, Eur Respir J, 2021 |
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial. |
| Tornero C, medrxiv, 2021 |
Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I) |
| Toroghi N, Pharmacol Rep, 2021 |
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial |
| Zhang Q, Infect Dis Ther, 2021 |
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2. |
These interventions were not prioritized but they might be included in the future. Details here